AbbVie Inc. (BMV:ABBV)

Market Cap	6.78T +11.4%
Revenue (ttm)	1.10T +8.6%
Net Income	76.08B -1.2%
EPS	42.49 -1.3%
Shares Out	n/a
PE Ratio	89.12
Forward PE	15.28
Dividend	124.74 (3.20%)
Ex-Dividend Date	Jan 16, 2026

Volume	n/a
Average Volume	1,156
Open	3,877.00
Previous Close	3,900.00
Day's Range	3,877.00 - 3,877.00
52-Week Range	3,343.00 - 4,529.31
Beta	0.35
RSI	47.18
Earnings Date	Feb 4, 2026

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: ABBV

Financial Performance

In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.23 billion, a decrease of -0.28%.

Financial numbers in USD